Scinovex
article Open Access

Analysis of homoeopathic genus epidemicus for COVID-19 patients in Gujarat: A retrospective cohort study

International Journal of Homoeopathic Sciences · 2021 · Vol. 5(4) · pp. 232–237
Ankit Kumar DubeyShail Dubey

Abstract

Background: In the last two centuries, homeopathy has successfully treated epidemics. Our goal is to obtain a clear homeopathic clinical picture of Corona virus Disease 2019 (COVID19) and to assume the prevalence of the disease in order to inform and strengthen future treatment and prevention options.Methods: We conducted a retrospective case series study, collecting data from the Parul Sewashram Hospital, Vadodara and four constituent homeopathic medical colleges of Parul University in Rajkot, Ahmedabad and Vadodara, which came from fever and/or cough and/or patients with dyspnea and/or confirmed COVID19 infection or close contact with confirmed patients. Include 280 patients and record data through checklist questionnaires on the day of case analysis and 10-15 days after starting treatment. Symptoms were collected and analyzed with the help of homeopathic repertories.Results: A total of 268 cases were mild and moderate; 12 were serious. Severe cases were excluded from the analysis, 268 mild and moderate cases were analyzed, and clear general clinical images with mental, general and peculiar symptoms were obtained. The most commonly prescribed medications are Bry, Ars, Phos and Gels, while the best responders are Sulph, Puls and Bry. The time to complete recovery after homeopathic treatment is 3 to 14 days, depending on the medication used. The efficacy of 200c is associated with a faster complete recovery rate.Conclusion: We have defined the homeopathic characteristics of mild and moderate COVID19 symptoms in Gujarat and established a set of medicines that can be used to treat them as effective epidemics.

Complementary and Alternative Medicine StudiesPhytochemicals and Medicinal PlantsCOVID-19 Clinical Research StudiesHomeopathyMedicineChecklistCoronavirus disease 2019 (COVID-19)Retrospective cohort studyCohortMedical recordInternal medicineDiseasePediatrics
Citations
0
FWCI
0.00
field-weighted impact
References
17
Percentile
26%
vs. same field & year
References
Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19
Critical Care · 2020 · 1,202 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.